{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:25:08Z","timestamp":1788200708584,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"73","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00982"],"award-info":[{"award-number":["PI21\/00982"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/02\/0073"],"award-info":[{"award-number":["CB06\/02\/0073"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon Europe research and innovation program","award":["101155975"],"award-info":[{"award-number":["101155975"]}]},{"name":"European Commission\u2019s EU4Health Programme Joint Actions PERCH"},{"name":"PartnERship to Contrast HPV","award":["101075314"],"award-info":[{"award-number":["101075314"]}]},{"name":"SHIELD\u2014Strategies for Health Interventions to Eliminate Infection related Cancers","award":["101233259"],"award-info":[{"award-number":["101233259"]}]},{"name":"Secretariat for Universities"},{"name":"Department of Business and Knowledge of the Government of Catalonia","award":["2021SGR01029"],"award-info":[{"award-number":["2021SGR01029"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA098252"],"award-info":[{"award-number":["P50CA098252"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA237067"],"award-info":[{"award-number":["R01CA237067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Our aspiration is a future with universal administration prior to exposure using simply delivered and affordable vaccines covering all high-risk human papillomavirus (HPV) types and other HPVs associated with significant morbidity. However, this scenario remains unrealized: no vaccine today covers the full range of high-risk HPV types, nor have we reached every population that needs HPV vaccination, so infection remains prevalent. The reasons are multifaceted, involving scientific, economic, sociocultural, and logistical hurdles, yet efforts are ongoing worldwide to overcome these challenges. Broad implementation of primary HPV-based screening, including self-sampling, will improve cervical cancer prevention and inform many more women of their high-risk HPV-positive status. Development of high-risk HPV-targeted therapeutics could further accelerate declines in cervical cancer by clearing prevalent infections. Progress on HPV vaccination and improvements in screening technology continue at a remarkable pace. Reduction in cervical cancer incidence is evident where vaccination and\/or screening have been adopted early and widely implemented.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag015","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:42:37Z","timestamp":1779363757000},"page":"137-147","source":"Crossref","is-referenced-by-count":1,"title":["Developments in human papillomavirus vaccines, schedules, and implementation strategies"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-0326","authenticated-orcid":false,"given":"Laia","family":"Bruni","sequence":"first","affiliation":[{"name":"Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP CB06\/02\/0073) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Brotons","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP CB06\/02\/0073) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-0195","authenticated-orcid":false,"given":"Richard B S","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104013861700_lgag015-B1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013861700_lgag015-B2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083104013861700_lgag015-B3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jnci\/djad263","article-title":"Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation","volume":"116","author":"Palmer","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013861700_lgag015-B4","author":"World Health Organization","year":"2020"},{"key":"2026083104013861700_lgag015-B5","first-page":"1","article-title":"Cervical cancer screening","volume":"18","author":"International Agency for Research on Cancer","year":"2022","journal-title":"IARC Handb Cancer Prev"},{"key":"2026083104013861700_lgag015-B6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"Roden","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2026083104013861700_lgag015-B7","author":"GxP News","year":"2025"},{"key":"2026083104013861700_lgag015-B8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jncimonographs\/lgae026","article-title":"Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy","volume":"2024","author":"Schuind","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026083104013861700_lgag015-B9","author":"World Health Organization","year":"2025"},{"key":"2026083104013861700_lgag015-B10","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update) \u2013vaccins contre les papillomavirus humains: note de synth\u00e8se de l\u2019OMS (mise \u00e0 jour de 2022)","volume":"97","author":"World Health Organization","year":"2022","journal-title":"WER"},{"key":"2026083104013861700_lgag015-B11","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1016\/j.vaccine.2009.05.019","article-title":"WHO position on HPV vaccines","volume":"27","author":"World Health Organization","year":"2009","journal-title":"Vaccine"},{"key":"2026083104013861700_lgag015-B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/vaccines12010004","article-title":"The global demand and supply balance of the human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer","volume":"12","author":"Malvolti","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026083104013861700_lgag015-B13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10198-018-0996-9","article-title":"Pricing of HPV vaccines in European tender-based settings","volume":"20","author":"Qendri","year":"2019","journal-title":"Eur J Health Econ"},{"key":"2026083104013861700_lgag015-B14","author":"UNICEF Supply Division","year":"2025"},{"key":"2026083104013861700_lgag015-B15","author":"World Health Organization","year":"2025"},{"key":"2026083104013861700_lgag015-B16","doi-asserted-by":"publisher","first-page":"e0291990","DOI":"10.1371\/journal.pone.0291990","article-title":"Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries","volume":"19","author":"Guillaume","year":"2024","journal-title":"PLoS One"},{"key":"2026083104013861700_lgag015-B17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013861700_lgag015-B18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013861700_lgag015-B19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/S1473-3099(25)00284-1","article-title":"Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial","volume":"25","author":"Cort\u00e9s","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026083104013861700_lgag015-B20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"2026083104013861700_lgag015-B21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","article-title":"HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: costa Rica HPV vaccine trial","volume":"2024","author":"Porras","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026083104013861700_lgag015-B22","doi-asserted-by":"publisher","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026083104013861700_lgag015-B23","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"key":"2026083104013861700_lgag015-B24","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","article-title":"Noninferiority of one HPV vaccine dose to two doses","volume":"393","author":"Kreimer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026083104013861700_lgag015-B25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/jncimonographs\/lgae042","article-title":"A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination","volume":"2024","author":"Malvi","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026083104013861700_lgag015-B26","doi-asserted-by":"publisher","first-page":"e788","DOI":"10.1016\/S2468-2667(23)00180-9","article-title":"Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis","volume":"8","author":"B\u00e9nard","year":"2023","journal-title":"Lancet Public Health"},{"key":"2026083104013861700_lgag015-B27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jncimonographs\/lgae030","article-title":"Single-dose human papillomavirus vaccination: an update","volume":"2024","author":"Kreimer","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026083104013861700_lgag015-B28","doi-asserted-by":"publisher","first-page":"e2153","DOI":"10.1016\/S2214-109X(25)00376-6","article-title":"Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis","volume":"13","author":"B\u00e9nard","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026083104013861700_lgag015-B29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2352-4642(18)30220-7","article-title":"Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study","volume":"2","author":"Silverberg","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2026083104013861700_lgag015-B30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"2026083104013861700_lgag015-B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026083104013861700_lgag015-B32","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Tsang","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013861700_lgag015-B33","author":"HPV Prevention and Control Board","year":"2025"},{"key":"2026083104013861700_lgag015-B34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","article-title":"Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies","volume":"18","author":"Lehtinen","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2026083104013861700_lgag015-B35","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/infdis\/jiaa099","article-title":"Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied","volume":"222","author":"V\u00e4nsk\u00e4","year":"2020","journal-title":"J Infect Dis"},{"key":"2026083104013861700_lgag015-B36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ijc.31409","article-title":"Impacts of human papillomavirus vaccination for different populations: a modeling study","volume":"143","author":"Baussano","year":"2018","journal-title":"Int J Cancer"},{"key":"2026083104013861700_lgag015-B37","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/ijc.34839","article-title":"Scientific approaches toward improving cervical cancer elimination strategies","volume":"154","author":"Lehtinen","year":"2024","journal-title":"Int J Cancer"},{"key":"2026083104013861700_lgag015-B38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12919-025-00337-1","article-title":"Accelerating HPV-related cancer elimination\u2013a meeting report","volume":"19","author":"Burdier","year":"2025","journal-title":"BMC Proc"},{"key":"2026083104013861700_lgag015-B39","doi-asserted-by":"publisher","first-page":"106827","DOI":"10.1016\/j.ypmed.2021.106827","article-title":"Prospects for accelerated elimination of cervical cancer","volume":"153","author":"Dillner","year":"2021","journal-title":"Prev Med"},{"key":"2026083104013861700_lgag015-B40","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1038\/s41467-024-47909-x","article-title":"Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer","volume":"15","author":"Arroyo M\u00fchr","year":"2024","journal-title":"Nat Commun"},{"key":"2026083104013861700_lgag015-B41","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1093\/infdis\/jiaf032","article-title":"Population-based age-period-cohort analysis of declining human papillomavirus prevalence","volume":"231","author":"Gray","year":"2025","journal-title":"J Infect Dis"},{"key":"2026083104013861700_lgag015-B42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/LGT.0000000000000865","article-title":"Applying results of extended genotyping to management of positive cervicovaginal human papillomavirus test results: enduring guidelines","volume":"29","author":"Massad","year":"2025","journal-title":"J Low Genit Tract Dis. Published"},{"key":"2026083104013861700_lgag015-B43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ijc.70148","article-title":"Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program","volume":"158","author":"Andersen","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104013861700_lgag015-B44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ijc.70119","article-title":"Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era","volume":"158","author":"Tota","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104013861700_lgag015-B45","doi-asserted-by":"publisher","first-page":"127576","DOI":"10.1016\/j.vaccine.2025.127576","article-title":"Evaluation of possible human papillomavirus (HPV) type replacement after vaccine introduction, overall and by race\/ethnicity, United States","volume":"62","author":"Brewer","year":"2025","journal-title":"Vaccine"},{"key":"2026083104013861700_lgag015-B46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/INF.0000000000002437","article-title":"Long-term immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 vaccine in four- to six-year-old girls: three-year follow-up of a randomized phase III trial","volume":"38","author":"Lin","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026083104013861700_lgag015-B47","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.4161\/hv.29617","article-title":"Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule","volume":"10","author":"Gilca","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026083104013861700_lgag015-B48","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3390\/cancers15061709","article-title":"Prevention and treatment of HPV-induced skin tumors","volume":"15","author":"Hasche","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026083104013861700_lgag015-B49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","article-title":"Development of a highly thermostable, adjuvanted human papillomavirus vaccine","volume":"94","author":"Hassett","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"2026083104013861700_lgag015-B50","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.xphs.2023.02.007","article-title":"A single dose, thermostable, trivalent human papillomavirus vaccine formulated using atomic layer deposition","volume":"112","author":"Witeof","year":"2023","journal-title":"J Pharm Sci"},{"key":"2026083104013861700_lgag015-B51","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"key":"2026083104013861700_lgag015-B52","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int J Cancer"},{"key":"2026083104013861700_lgag015-B53","doi-asserted-by":"publisher","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"2026083104013861700_lgag015-B54","doi-asserted-by":"publisher","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2026083104013861700_lgag015-B55","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026083104013861700_lgag015-B56","doi-asserted-by":"publisher","first-page":"126100","DOI":"10.1016\/j.vaccine.2024.07.001","article-title":"Meeting report: considerations for trial design and endpoints in licensing therapeutic HPV16\/18 vaccines to prevent cervical cancer","volume":"42","author":"Dull","year":"2024","journal-title":"Vaccine"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/137\/70870281\/lgag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/137\/70870281\/lgag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:45Z","timestamp":1788163305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/137\/8776094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":56,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag015","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}